Prognostic significance of programmed cell death 1 expression on CD8+T cells in various cancers: a systematic review and meta-analysis

Increased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducte...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 14; p. 1531219
Main Authors Wan, Zhiyong, Cui, Meng, Yang, Jia, Liao, Dan, Chen, Junliang, Li, Fanmin, Xiang, Yin, Cui, Zhiwei, Yang, Yang
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 14.01.2025
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Increased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducted a meta-analysis to evaluate its prognostic value in human cancers. PRISMA reporting guidelines were strictly followed for conducting the current meta-analysis. The PubMed, Web of Science, Embase databases were searched from inception to November 2024. The pooled Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined for the associations of PD-1+CD8+ T cells with overall survival (OS), progression- free survival (PFS) and disease-free survival(DFS). Subgroup analyses were performed for area, specimen type, cancer type, treatment, detected method and cancer stage. A total of 20 studies (23 cohorts, 3086 cancer patients) were included in our study. The expression PD-1+CD8+ T cells in cancer patients tended to predict poor overall survival (OS) (HR: 1.379, 95%CI: 1.084-1.753, = 0.009), and unfavorable disease-free survival(DFS) (HR: 1.468, 95%CI: 0.931-2.316, =0.099), though it did not reach statistical significance. Begg's and Egger's test demonstrated that no obvious publication bias was exist. High PD-1 expression on CD8+ T cells is associated with worse survival outcomes, which can be potentially used as a prognostic marker of malignant tumor.
AbstractList Increased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducted a meta-analysis to evaluate its prognostic value in human cancers.BackgroundIncreased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducted a meta-analysis to evaluate its prognostic value in human cancers.PRISMA reporting guidelines were strictly followed for conducting the current meta-analysis. The PubMed, Web of Science, Embase databases were searched from inception to November 2024. The pooled Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined for the associations of PD-1+CD8+ T cells with overall survival (OS), progression- free survival (PFS) and disease-free survival(DFS). Subgroup analyses were performed for area, specimen type, cancer type, treatment, detected method and cancer stage.MethodsPRISMA reporting guidelines were strictly followed for conducting the current meta-analysis. The PubMed, Web of Science, Embase databases were searched from inception to November 2024. The pooled Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined for the associations of PD-1+CD8+ T cells with overall survival (OS), progression- free survival (PFS) and disease-free survival(DFS). Subgroup analyses were performed for area, specimen type, cancer type, treatment, detected method and cancer stage.A total of 20 studies (23 cohorts, 3086 cancer patients) were included in our study. The expression PD-1+CD8+ T cells in cancer patients tended to predict poor overall survival (OS) (HR: 1.379, 95%CI: 1.084-1.753, p= 0.009), and unfavorable disease-free survival(DFS) (HR: 1.468, 95%CI: 0.931-2.316, p=0.099), though it did not reach statistical significance. Begg's and Egger's test demonstrated that no obvious publication bias was exist.ResultsA total of 20 studies (23 cohorts, 3086 cancer patients) were included in our study. The expression PD-1+CD8+ T cells in cancer patients tended to predict poor overall survival (OS) (HR: 1.379, 95%CI: 1.084-1.753, p= 0.009), and unfavorable disease-free survival(DFS) (HR: 1.468, 95%CI: 0.931-2.316, p=0.099), though it did not reach statistical significance. Begg's and Egger's test demonstrated that no obvious publication bias was exist.High PD-1 expression on CD8+ T cells is associated with worse survival outcomes, which can be potentially used as a prognostic marker of malignant tumor.ConclusionsHigh PD-1 expression on CD8+ T cells is associated with worse survival outcomes, which can be potentially used as a prognostic marker of malignant tumor.
BackgroundIncreased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducted a meta-analysis to evaluate its prognostic value in human cancers.MethodsPRISMA reporting guidelines were strictly followed for conducting the current meta-analysis. The PubMed, Web of Science, Embase databases were searched from inception to November 2024. The pooled Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined for the associations of PD-1+CD8+ T cells with overall survival (OS), progression- free survival (PFS) and disease-free survival(DFS). Subgroup analyses were performed for area, specimen type, cancer type, treatment, detected method and cancer stage.ResultsA total of 20 studies (23 cohorts, 3086 cancer patients) were included in our study. The expression PD-1+CD8+ T cells in cancer patients tended to predict poor overall survival (OS) (HR: 1.379, 95%CI: 1.084-1.753, p= 0.009), and unfavorable disease-free survival(DFS) (HR: 1.468, 95%CI: 0.931-2.316, p=0.099), though it did not reach statistical significance. Begg’s and Egger’s test demonstrated that no obvious publication bias was exist.ConclusionsHigh PD-1 expression on CD8+ T cells is associated with worse survival outcomes, which can be potentially used as a prognostic marker of malignant tumor.
Increased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducted a meta-analysis to evaluate its prognostic value in human cancers. PRISMA reporting guidelines were strictly followed for conducting the current meta-analysis. The PubMed, Web of Science, Embase databases were searched from inception to November 2024. The pooled Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined for the associations of PD-1+CD8+ T cells with overall survival (OS), progression- free survival (PFS) and disease-free survival(DFS). Subgroup analyses were performed for area, specimen type, cancer type, treatment, detected method and cancer stage. A total of 20 studies (23 cohorts, 3086 cancer patients) were included in our study. The expression PD-1+CD8+ T cells in cancer patients tended to predict poor overall survival (OS) (HR: 1.379, 95%CI: 1.084-1.753, = 0.009), and unfavorable disease-free survival(DFS) (HR: 1.468, 95%CI: 0.931-2.316, =0.099), though it did not reach statistical significance. Begg's and Egger's test demonstrated that no obvious publication bias was exist. High PD-1 expression on CD8+ T cells is associated with worse survival outcomes, which can be potentially used as a prognostic marker of malignant tumor.
Author Cui, Meng
Wan, Zhiyong
Yang, Jia
Li, Fanmin
Chen, Junliang
Liao, Dan
Cui, Zhiwei
Yang, Yang
Xiang, Yin
AuthorAffiliation 1 Department of General Practice, People’s Hospital of Leshan , Leshan , China
2 Department of Medical Laboratory, People’s Hospital of Leshan , Leshan , China
AuthorAffiliation_xml – name: 1 Department of General Practice, People’s Hospital of Leshan , Leshan , China
– name: 2 Department of Medical Laboratory, People’s Hospital of Leshan , Leshan , China
Author_xml – sequence: 1
  givenname: Zhiyong
  surname: Wan
  fullname: Wan, Zhiyong
– sequence: 2
  givenname: Meng
  surname: Cui
  fullname: Cui, Meng
– sequence: 3
  givenname: Jia
  surname: Yang
  fullname: Yang, Jia
– sequence: 4
  givenname: Dan
  surname: Liao
  fullname: Liao, Dan
– sequence: 5
  givenname: Junliang
  surname: Chen
  fullname: Chen, Junliang
– sequence: 6
  givenname: Fanmin
  surname: Li
  fullname: Li, Fanmin
– sequence: 7
  givenname: Yin
  surname: Xiang
  fullname: Xiang, Yin
– sequence: 8
  givenname: Zhiwei
  surname: Cui
  fullname: Cui, Zhiwei
– sequence: 9
  givenname: Yang
  surname: Yang
  fullname: Yang, Yang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39876901$$D View this record in MEDLINE/PubMed
BookMark eNpVkt1q3DAQhU1JadI0D9CbostC8VZ_tuXelLLpTyDQXqTQOzGWRhsFW9pK3m33BfLctXe3IRECDZrDd8TovCxOQgxYFK8ZXQih2vcuBrPglMsFqwTjrH1WnHEuZNlK8evkUX1aXOR8R6dVV5RR8aI4Fa1q6pays-L-R4qrEPPoDcl-FbzzBoJBEh1ZT60Ew4CWGOx7YhHGW8II_l0nzNnHQKa9vFTvbvaCTHwgW0g-bjLZU1L-QIDkXR5xgNki4dbjHwLBkgFHKCFAv8s-vyqeO-gzXhzP8-Lnl883y2_l9fevV8tP16WRTI2lxMrYWkJXd1UnhHEgpROmEhIM64TpWovcWmNczeuGW-UUqxUXjVNcWobivLg6cG2EO71OfoC00xG83l_EtNKQpof2qCvOuLIgOodcKmwVZd3kx0QHLUXnJtbHA2u96aYZGQxjgv4J9Gkn-Fu9ilvNWNNwTquJ8PZISPH3BvOoB5_nSULAaYZasJq2oq2rWfrmsdmDy_-fnATsIDAp5pzQPUgY1XNg9BwYPQdGHwMj_gH6l7b3
Cites_doi 10.1136/jitc-2019-000422
10.1182/blood-2008-12-195792
10.1158/0008-5472.CAN-16-3167
10.1007/s00262-018-2138-8
10.21873/anticanres.13132
10.1136/jitc-2023-007585
10.1186/s40880-017-0226-3
10.1186/s40425-019-0499-y
10.1158/1078-0432.CCR-19-3003
10.1038/modpathol.2010.130
10.1158/1078-0432.CCR-17-2156
10.1016/j.radonc.2015.07.003
10.1038/s41467-018-06653-9
10.1007/s10120-023-01364-7
10.1056/NEJMoa1606774
10.1146/annurev.immunol.26.021607.090331
10.1038/s41591-018-0057-z
10.18632/oncotarget.5583
10.1038/s41598-017-08479-9
10.1073/pnas.1705327114
10.3390/biomedicines10112794
10.1038/nature10673
10.1177/1758835919853193
10.1186/s40425-019-0814-7
10.1016/j.lungcan.2018.11.038
10.1016/j.cellimm.2017.01.001
10.1056/NEJMoa1809615
10.1016/j.it.2013.10.001
10.1007/s10654-010-9491-z
10.1080/2162402X.2015.1062969
10.3390/cancers15153955
10.1111/cas.12502
10.1038/nature05115
10.1016/j.coi.2014.01.004
10.3389/fonc.2022.837560
10.1042/CS20191261
10.1172/JCI46102
10.1038/s41590-020-0769-3
10.3390/cancers15051389
10.1126/science.1203486
10.1002/ijc.25397
10.1038/s41416-022-01939-8
10.1056/NEJMoa1801005
10.1177/00045632231184716
10.1158/2326-6066.CIR-15-0097
ContentType Journal Article
Copyright Copyright © 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang.
Copyright © 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang
Copyright_xml – notice: Copyright © 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang.
– notice: Copyright © 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fonc.2024.1531219
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
ExternalDocumentID oai_doaj_org_article_52128da3bfe248e9801bfa413ba90eff
PMC11772205
39876901
10_3389_fonc_2024_1531219
Genre Journal Article
Review
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c418t-4e5cd64ab6b5b33cfa44f3c534ac1b3cb9de2ddccf62672d8f8168237f824d1e3
IEDL.DBID M48
ISSN 2234-943X
IngestDate Wed Aug 27 01:18:39 EDT 2025
Thu Aug 21 18:40:30 EDT 2025
Fri Jul 11 11:00:15 EDT 2025
Fri Jan 31 01:44:33 EST 2025
Tue Jul 01 01:56:10 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords overall survival
cancer
PD-1+CD8+ T cells
disease-free survival
progression-free survival
Language English
License Copyright © 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c418t-4e5cd64ab6b5b33cfa44f3c534ac1b3cb9de2ddccf62672d8f8168237f824d1e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Yu’e Liu, Boston Children’s Hospital and Harvard Medical School, United States
Reviewed by: Jin-Ming Zhang, University of Texas Health Science Center at Houston, United States
These authors have contributed equally to this work
Xutong Xue, Boston Children’s Hospital and Harvard Medical School, United States
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2024.1531219
PMID 39876901
PQID 3160939655
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_52128da3bfe248e9801bfa413ba90eff
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11772205
proquest_miscellaneous_3160939655
pubmed_primary_39876901
crossref_primary_10_3389_fonc_2024_1531219
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-01-14
PublicationDateYYYYMMDD 2025-01-14
PublicationDate_xml – month: 01
  year: 2025
  text: 2025-01-14
  day: 14
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in oncology
PublicationTitleAlternate Front Oncol
PublicationYear 2025
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Kansy (B23) 2017; 77
Thommen (B8) 2015; 3
Lu (B35) 2017; 313
Baitsch (B5) 2011; 121
Mazzaschi (B20) 2018; 24
Homicsko (B31) 2023; 11
Mellman (B2) 2011; 480
Schreiner (B9) 2016; 5
Choo (B17) 2023; 26
Schmid (B41) 2018; 379
Kamphorst (B43) 2017; 114
Gao (B28) 2017; 36
Ahmadzadeh (B11) 2009; 114
Keir (B6) 2008; 26
Schietinger (B4) 2014; 35
Zhu (B42) 2022; 12
Pokryvkova (B14) 2022; 10
Thommen (B16) 2018; 24
Waki (B22) 2014; 105
Saito (B21) 2019; 39
Yang (B32) 2023; 15
Shen (B29) 2017; 7
Yu (B19) 2022; 127
Tang (B25) 2020; 26
Kumagai (B44) 2020; 21
Day (B7) 2006; 443
Guo (B27) 2020; 134
Kotsakis (B33) 2019; 11
Egelston (B39) 2018; 9
Varki (B34) 2018; 67
Mittal (B1) 2014; 27
Stang (B15) 2010; 25
Shen (B37) 2020; 8
Qin (B38) 2015; 6
Shin (B18) 2023; 15
Lim (B36) 2015; 117
Reck (B40) 2016; 375
Gandhi (B45) 2018; 378
Hsu (B12) 2010; 23
Mazzaschi (B26) 2019; 127
You (B24) 2024; 61
Yeong (B30) 2019; 7
Schreiber (B3) 2011; 331
Shi (B10) 2011; 128
Ma (B13) 2019; 7
References_xml – volume: 8
  year: 2020
  ident: B37
  article-title: Pd-1 does not mark tumor-infiltrating Cd8+ T cell dysfunction in human gastric cancer
  publication-title: J immunotherapy Cancer
  doi: 10.1136/jitc-2019-000422
– volume: 114
  year: 2009
  ident: B11
  article-title: Tumor antigen-specific Cd8 T cells infiltrating the tumor express high levels of Pd-1 and are functionally impaired
  publication-title: Blood
  doi: 10.1182/blood-2008-12-195792
– volume: 77
  year: 2017
  ident: B23
  article-title: Pd-1 status in Cd8(+) T cells associates with survival and anti-Pd-1 therapeutic outcomes in head and neck cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-3167
– volume: 67
  year: 2018
  ident: B34
  article-title: Pd-L1, B7-H3, and Pd-1 expression in immunocompetent vs. Immunosuppressed patients with cutaneous squamous cell carcinoma
  publication-title: Cancer immunology immunotherapy: CII
  doi: 10.1007/s00262-018-2138-8
– volume: 39
  year: 2019
  ident: B21
  article-title: Pd-1 expression on circulating Cd8(+) T-cells as a prognostic marker for patients with gastric cancer
  publication-title: Anticancer Res
  doi: 10.21873/anticanres.13132
– volume: 11
  year: 2023
  ident: B31
  article-title: Pd-1-expressing macrophages and Cd8 T cells are independent predictors of clinical benefit from Pd-1 inhibition in advanced mesothelioma
  publication-title: J immunotherapy Cancer
  doi: 10.1136/jitc-2023-007585
– volume: 36
  start-page: 61
  year: 2017
  ident: B28
  article-title: Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and Cd8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4n+M0 gastric adenocarcinoma
  publication-title: Chin J Cancer
  doi: 10.1186/s40880-017-0226-3
– volume: 7
  start-page: 34
  year: 2019
  ident: B30
  article-title: Prognostic value of Cd8 + Pd-1+ Immune infiltrates and Pdcd1 gene expression in triple negative breast cancer
  publication-title: J immunotherapy Cancer
  doi: 10.1186/s40425-019-0499-y
– volume: 26
  year: 2020
  ident: B25
  article-title: Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-3003
– volume: 23
  year: 2010
  ident: B12
  article-title: Increase of programmed death-1-expressing intratumoral Cd8 T cells predicts a poor prognosis for nasopharyngeal carcinoma
  publication-title: Modern Pathol
  doi: 10.1038/modpathol.2010.130
– volume: 24
  year: 2018
  ident: B20
  article-title: Low Pd-1 expression in cytotoxic Cd8(+) tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in Nsclc with a prognostic and predictive value
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-2156
– volume: 117
  year: 2015
  ident: B36
  article-title: High ratio of programmed cell death protein 1 (Pd-1)(+)/Cd8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy
  publication-title: Radiotherapy Oncol
  doi: 10.1016/j.radonc.2015.07.003
– volume: 9
  start-page: 4297
  year: 2018
  ident: B39
  article-title: Human breast tumor-infiltrating Cd8(+) T cells retain polyfunctionality despite Pd-1 expression
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-06653-9
– volume: 26
  start-page: 393
  year: 2023
  ident: B17
  article-title: Clinical relevance of Pd-1 positive Cd8 T-cells in gastric cancer
  publication-title: Gastric Cancer
  doi: 10.1007/s10120-023-01364-7
– volume: 375
  year: 2016
  ident: B40
  article-title: Pembrolizumab versus chemotherapy for Pd-L1-positive non-small-cell lung cancer
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa1606774
– volume: 26
  start-page: 677
  year: 2008
  ident: B6
  article-title: Pd-1 and its ligands in tolerance and immunity
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.immunol.26.021607.090331
– volume: 24
  start-page: 994
  year: 2018
  ident: B16
  article-title: A transcriptionally and functionally distinct Pd-1(+) Cd8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with Pd-1 blockade
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0057-z
– volume: 6
  year: 2015
  ident: B38
  article-title: High Pd-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.5583
– volume: 7
  start-page: 7848
  year: 2017
  ident: B29
  article-title: Prognostic value of programmed cell death protein 1 expression on Cd8+ T lymphocytes in pancreatic cancer
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-08479-9
– volume: 114
  year: 2017
  ident: B43
  article-title: Proliferation of Pd-1+ Cd8 T cells in peripheral blood after Pd-1-targeted therapy in lung cancer patients
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1705327114
– volume: 10
  year: 2022
  ident: B14
  article-title: Pd1(+)Cd8(+) cells are an independent prognostic marker in patients with head and neck cancer
  publication-title: Biomedicines
  doi: 10.3390/biomedicines10112794
– volume: 480
  year: 2011
  ident: B2
  article-title: Cancer immunotherapy comes of age
  publication-title: Nature
  doi: 10.1038/nature10673
– volume: 11
  year: 2019
  ident: B33
  article-title: Cd8(+) Pd-1(+) T-cells and Pd-L1(+) circulating tumor cells in chemotherapy-naive non-small cell lung cancer: towards their clinical relevance
  publication-title: Ther Adv Med Oncol
  doi: 10.1177/1758835919853193
– volume: 7
  start-page: 331
  year: 2019
  ident: B13
  article-title: Pd1(Hi) Cd8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma
  publication-title: J immunotherapy Cancer
  doi: 10.1186/s40425-019-0814-7
– volume: 127
  year: 2019
  ident: B26
  article-title: The circulating pool of functionally competent Nk and Cd8+ Cells predicts the outcome of anti-Pd1 treatment in advanced Nsclc
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.11.038
– volume: 313
  start-page: 43
  year: 2017
  ident: B35
  article-title: Tumor antigen-specific Cd8(+) T cells are negatively regulated by Pd-1 and Tim-3 in human gastric cancer
  publication-title: Cell Immunol
  doi: 10.1016/j.cellimm.2017.01.001
– volume: 379
  year: 2018
  ident: B41
  article-title: Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa1809615
– volume: 35
  start-page: 51
  year: 2014
  ident: B4
  article-title: Tolerance and exhaustion: defining mechanisms of T cell dysfunction
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2013.10.001
– volume: 25
  year: 2010
  ident: B15
  article-title: Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
  publication-title: Eur J Epidemiol
  doi: 10.1007/s10654-010-9491-z
– volume: 5
  start-page: e1062969
  year: 2016
  ident: B9
  article-title: Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2015.1062969
– volume: 15
  year: 2023
  ident: B18
  article-title: Early increase in circulating Pd-1(+)Cd8(+) T cells predicts favorable survival in patients with advanced gastric cancer receiving chemotherapy
  publication-title: Cancers
  doi: 10.3390/cancers15153955
– volume: 105
  year: 2014
  ident: B22
  article-title: Pd-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
  publication-title: Cancer Sci
  doi: 10.1111/cas.12502
– volume: 443
  year: 2006
  ident: B7
  article-title: Pd-1 expression on Hiv-specific T cells is associated with T-cell exhaustion and disease progression
  publication-title: Nature
  doi: 10.1038/nature05115
– volume: 27
  start-page: 16
  year: 2014
  ident: B1
  article-title: New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape
  publication-title: Curr Opin Immunol
  doi: 10.1016/j.coi.2014.01.004
– volume: 12
  year: 2022
  ident: B42
  article-title: Restored Cd8(+)Pd-1(+) T cells facilitate the response to anti-Pd-1 for patients with pancreatic ductal adenocarcinoma
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.837560
– volume: 134
  year: 2020
  ident: B27
  article-title: Tumoral Pd-1hicd8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer
  publication-title: Clin Sci
  doi: 10.1042/CS20191261
– volume: 121
  year: 2011
  ident: B5
  article-title: Exhaustion of tumor-specific Cd8(+) T cells in metastases from melanoma patients
  publication-title: J Clin Invest
  doi: 10.1172/JCI46102
– volume: 21
  year: 2020
  ident: B44
  article-title: The Pd-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of Pd-1 blockade therapies
  publication-title: Nat Immunol
  doi: 10.1038/s41590-020-0769-3
– volume: 15
  year: 2023
  ident: B32
  article-title: Pd-1(+)Cd8(+) T cells proximal to Pd-L1(+)Cd68(+) macrophages are associated with poor prognosis in pancreatic ductal adenocarcinoma patients
  publication-title: Cancers
  doi: 10.3390/cancers15051389
– volume: 331
  year: 2011
  ident: B3
  article-title: Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion
  publication-title: Science
  doi: 10.1126/science.1203486
– volume: 128
  year: 2011
  ident: B10
  article-title: Pd-1 and Pd-L1 upregulation promotes Cd8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
  publication-title: Int J Cancer
  doi: 10.1002/ijc.25397
– volume: 127
  year: 2022
  ident: B19
  article-title: Intratumoral Pd-1(+)Cd8(+) T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer
  publication-title: Br J Cancer
  doi: 10.1038/s41416-022-01939-8
– volume: 378
  year: 2018
  ident: B45
  article-title: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa1801005
– volume: 61
  start-page: 79
  year: 2024
  ident: B24
  article-title: Increased Pd-1 expression of bone marrow T-cells in acute myeloid leukaemia patients after stem cell transplantation, and its association with overall survival
  publication-title: Ann Clin Biochem
  doi: 10.1177/00045632231184716
– volume: 3
  year: 2015
  ident: B8
  article-title: Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-15-0097
SSID ssj0000650103
Score 2.3781142
SecondaryResourceType review_article
Snippet Increased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients....
BackgroundIncreased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1531219
SubjectTerms cancer
disease-free survival
Oncology
overall survival
PD-1+CD8+ T cells
progression-free survival
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA6yB_Eivm1flOBJiTt5Tsebri6LsOJhF_YW8sQ9mJaZWfEX-Lut6u5dZ0TwIvSpO6RDfZVKVVL5irEX0WqzVCVyo6viOsrMwyJK7sh9Fuhw10xbA8ef7NGp_nhmzrZKfVFO2EQPPAlun-6W9jmoWIvUfXFoUWMNaHpjcItSK1lfXPO2gqnJBhsqYDAdY2IU5vbr0IixUOrXOMeFJGadrYVo5Ov_m5P5Z67k1uJzeIvdnL1GeDuN9ja7Vtoddv14Phe_y35-Xg2UMYefgTIyKP-H4IShwpyBhZ0D7dJDJqcPBJQfcw5sA3wO3vevTsYGazhv8B1D6OFiDWMvq_UbCPCb8xmm-y4QWoavZRN4mJlN7rHTww8nB0d8rrDAkxb9hutiUrY6RBtNVCqhYBGyZJQOSUSVostF5pxSxbhnKXNfqUyHVMvaS51FUffZXhtaechAhaySEBU9kiXZBVeSstmWPutsZSode3kpbv9tItLwGIAQNp6w8YSNn7Hp2DsC5KohcWCPL1Az_KwZ_l-a0bHnl3B6nDMkwdAKys4rYRdOOWtMxx5M8F79SjlcH9BJ6li_A_zOWHa_tPMvIy83nX_TveVH_2P0j9kNSaWGF4IL_YTtbVYX5Sn6P5v4bFT1X30cBtk
  priority: 102
  providerName: Directory of Open Access Journals
Title Prognostic significance of programmed cell death 1 expression on CD8+T cells in various cancers: a systematic review and meta-analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/39876901
https://www.proquest.com/docview/3160939655
https://pubmed.ncbi.nlm.nih.gov/PMC11772205
https://doaj.org/article/52128da3bfe248e9801bfa413ba90eff
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIiEuqLxToDISJ1DK-pmkEkJQKBXSIg5daW-Rn1CpdSC7ReUP9Hczk3gLi_aEFOUQ23n4y3i-scczhDy3WqpKBFsqGUUpLfelmVheNkifGRDu6HFqYPpZH8_kp7mab5FVeqvcgYuNph3mk5r1Z_uXP369AYF_jRYn6NtXsUsYjJDLfRBfxjEI6A1QTBXK6TSz_XFgVpjVYFzb3NxyTTsNQfw3Mc9_HSj_0khHO-R2ppL07Yj9HbIV0l1yc5oXy--Rqy99h250UEzRTQOdghBj2kWa3bLg5hSn7qlHJkgZDZfZMTZROA7f1y9PhgoLeproT7Cru4sFHe7SLw6ooX8CQdNxEww1ydPzsDSlyeFO7pPZ0YeTw-Myp10onWT1spRBOa-lsdoqK4SLRgKOTglpHLPC2cYH7r1zEYyhivs6Yu4OLqpYc-lZEA_IdupSeESoMF44xiLQlAoHiyY4ob0OtZdecxcK8mLV3e33MbpGC1YJYtMiNi1i02ZsCvIOAbmuiIGxhwtd_7XNctbiVuTaG2Fj4LIODShgCx_AhDXNJMRYkGcrOFsQJOxBkwL0XSuYnjSi0UoV5OEI7_WjRANKA5hTQeo14NfeZb0knX4bgnXjojhuZt79_6aPyS2OWYcnrGTyCdle9hfhKVChpd0bphDg_HHO9oaf_TdZBA7a
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+significance+of+programmed+cell+death+1+expression+on+CD8%2BT+cells+in+various+cancers%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Frontiers+in+oncology&rft.au=Wan%2C+Zhiyong&rft.au=Cui%2C+Meng&rft.au=Yang%2C+Jia&rft.au=Liao%2C+Dan&rft.date=2025-01-14&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=14&rft_id=info:doi/10.3389%2Ffonc.2024.1531219&rft.externalDocID=PMC11772205
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon